215 related articles for article (PubMed ID: 22110219)
1. Investigative clinical study on prostate cancer part VII: prolactin and the pituitary-testis-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
Porcaro AB; Ghimenton C; Petrozziello A; Migliorini F; Romano M; Sava T; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C; Comunale L
Anticancer Res; 2011 Nov; 31(11):3913-20. PubMed ID: 22110219
[TBL] [Abstract][Full Text] [Related]
2. Investigative clinical study on prostate cancer part VIII: prolactin hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
Porcaro AB; Ghimenton C; Petrozziello A; Migliorini F; Romano M; Sava T; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C; Comunale L
Anticancer Res; 2012 Apr; 32(4):1499-506. PubMed ID: 22493393
[TBL] [Abstract][Full Text] [Related]
3. Investigative clinical study on prostate cancer part VI: Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
Porcaro AB; Migliorini F; Petrozziello A; Sava T; Romano M; Caruso B; Cocco C; Ghimenton C; Zecchinini Antoniolli S; Lacola V; Rubilotta E; Monaco C; Comunale L
Urol Int; 2012; 88(2):150-7. PubMed ID: 22205171
[TBL] [Abstract][Full Text] [Related]
4. Investigative clinical study on prostate cancer part IX and X: estradiol and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
Porcaro AB; Ghimenton C; Petrozziello A; Sava T; Migliorini F; Romano M; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C
Anticancer Res; 2012 Oct; 32(10):4523-32. PubMed ID: 23060581
[TBL] [Abstract][Full Text] [Related]
5. Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis of prostate cancer and subsequent cluster selection of the patient population undergoing standard radical prostatectomy.
Porcaro AB; Migliorini F; Petrozziello A; Sava T; Romano M; Caruso B; Cocco C; Ghimenton C; Zecchinini Antoniolli S; Lacola V; Rubilotta E; Monaco C; Comunale L
Urol Int; 2013; 90(1):45-55. PubMed ID: 23128438
[TBL] [Abstract][Full Text] [Related]
6. Along the pituitary-testis-prostate axis, serum total testosterone is a significant preoperative variable independently contributing to separating the prostate cancer population into prostatectomy Gleason score groups.
Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Cocco C; Romano M; Artibani W
Anticancer Res; 2012 Nov; 32(11):5015-22. PubMed ID: 23155273
[TBL] [Abstract][Full Text] [Related]
7. Investigative clinical study on prostate cancer Part V: Luteinizing hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
Porcaro AB; Petrozziello A; Migliorini F; Caruso B; Cocco C; Sava T; Ghimenton C; Romano M; Monaco C; Comunale L
Anticancer Res; 2011 Mar; 31(3):1071-8. PubMed ID: 21498741
[TBL] [Abstract][Full Text] [Related]
8. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
9. Investigative clinical study on prostate cancer part IV: exploring functional relationships of total testosterone predicting free testosterone and total prostate-specific antigen in operated prostate cancer patients.
Porcaro AB; Petrozziello A; Migliorini F; Lacola V; Romano M; Sava T; Ghimenton C; Caruso B; Zecchini Antoniolli S; Rubilotta E; Monaco C; Comunale L
Urol Int; 2011; 86(4):399-406. PubMed ID: 21508618
[TBL] [Abstract][Full Text] [Related]
10. [Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements].
Bantis A; Zissimopoulos A; Athanasiadou P; Gonidi M; Agelonidou E; Strataki A; Matthaios D; Tsartsarakis A
Hell J Nucl Med; 2007; 10(1):56-61. PubMed ID: 17450256
[TBL] [Abstract][Full Text] [Related]
11. Influence of radical prostatectomy on serum hormone levels.
Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
[TBL] [Abstract][Full Text] [Related]
12. Associations of pretreatment serum total testosterone measurements with pathology-detected Gleason score cancer.
Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Romano M; Cavalleri S; Artibani W
Urol Int; 2014; 93(3):269-78. PubMed ID: 24334919
[TBL] [Abstract][Full Text] [Related]
13. Serum total testosterone is a significant preoperative variable independently contributing to separating the prostate cancer population into prostatectomy Gleason score groups.
Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Cocco C; Romano M; Cavalleri S; Artibani W
Urol Int; 2013; 91(1):55-61. PubMed ID: 23751412
[TBL] [Abstract][Full Text] [Related]
14. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
15. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy.
Heracek J; Urban M; Sachova J; Kuncova J; Eis V; Mandys V; Hampl R; Starka L
Neuro Endocrinol Lett; 2007 Feb; 28(1):45-51. PubMed ID: 17277727
[TBL] [Abstract][Full Text] [Related]
16. Investigative clinical study on prostate cancer part III: exploring total PSA and free testosterone distributions and linear correlations in groups and subgroups of operated prostate cancer patients according to the total PSA/FT ratio.
Porcaro AB; Petrozziello A; Romano M; Sava T; Ghimenton C; Caruso B; Migliorini F; Zecchini Antoniolli S; Rubilotta E; Lacola V; Monaco C; Comunale L
Urol Int; 2010; 85(4):406-9. PubMed ID: 20948186
[TBL] [Abstract][Full Text] [Related]
17. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
18. [Interdependence between hormonal disorders, staging and degree of malignancy of prostatic gland cancer. 2].
Szymanowski J; Baranowska B; Rozbicka G; Jeske W; Zgliczynski S
J Urol (Paris); 1983; 89(9):663-8. PubMed ID: 6425418
[TBL] [Abstract][Full Text] [Related]
19. The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy.
Porcaro AB; Caruso B; Terrin A; De Luyk N; Cacciamani G; Corsi P; Inverardi D; De Marchi D; Baldassarre R; Cerruto M; Ghimenton C; Brunelli M; Zecchini Antoniolli S; Petrozziello A; Artibani W
Arch Ital Urol Androl; 2016 Mar; 88(1):17-22. PubMed ID: 27072171
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
Schatzl G; Marberger M; Remzi M; Grösser P; Unterlechner J; Haidinger G; Zidek T; Preyer M; Micksche M; Gsur A
Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
